Up­dat­ed: Sam­sung wins FDA ap­proval for sec­ond Soliris biosim­i­lar

Sam­sung Bioepis said Mon­day that the FDA ap­proved its biosim­i­lar to As­traZeneca’s block­buster im­muno­sup­pres­sive drug Soliris. And now the com­pa­ny is say­ing that the ap­proval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER